These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 20716138)

  • 1. Not yet time for a paradigm shift away from angiotensin inhibitors in chronic kidney disease, but due diligence required.
    Swift PA; Andrews PA
    Int J Clin Pract; 2010 Sep; 64(10):1331-3. PubMed ID: 20716138
    [No Abstract]   [Full Text] [Related]  

  • 2. Is renoprotection with RAAS blockade a failed paradigm? Have we learnt any lessons so far?
    Onuigbo MA
    Int J Clin Pract; 2010 Sep; 64(10):1341-6. PubMed ID: 20716141
    [No Abstract]   [Full Text] [Related]  

  • 3. Renoprotective effects of renin-angiotensin-aldosterone system blockers in type 2 diabetes: demystifying multiple treatment comparisons in a network meta-analysis.
    Catalá-López F
    Diabetologia; 2012 Sep; 55(9):2547-8; author reply 2549-50. PubMed ID: 22729654
    [No Abstract]   [Full Text] [Related]  

  • 4. Do inhibitors of the rennin-angiotensin system prevent chronic kidney disease?
    Rayner B
    Cardiovasc J Afr; 2010; 21(1):3-6. PubMed ID: 20224837
    [No Abstract]   [Full Text] [Related]  

  • 5. [Renin inhibition and the kidney].
    Ecder T
    Turk Kardiyol Dern Ars; 2009 Oct; 37 Suppl 7():28-31. PubMed ID: 20019474
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined blockade of the renin-angiotensin system with angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists.
    Azizi M; Ménard J
    Circulation; 2004 Jun; 109(21):2492-9. PubMed ID: 15173039
    [No Abstract]   [Full Text] [Related]  

  • 7. [Significance of RAAS inhibition in diabetic nephropathy].
    Tsuruya K; Toyonaga J
    Nihon Rinsho; 2012 Jul; 70 Suppl 5():411-8. PubMed ID: 23156430
    [No Abstract]   [Full Text] [Related]  

  • 8. Blockers of the renin-angiotensin-aldosterone system: almost, but not yet, an absolute weapon against cardiovascular and renal diseases!
    Waeber B
    J Renin Angiotensin Aldosterone Syst; 2012 Mar; 13(1):216. PubMed ID: 22389390
    [No Abstract]   [Full Text] [Related]  

  • 9. RAS blockade: new possibilities in the treatment of complications of diabetes.
    Ruilope L
    Heart; 2000 Sep; 84 Suppl 1(Suppl 1):i32-4:discussion i50. PubMed ID: 10956319
    [No Abstract]   [Full Text] [Related]  

  • 10. [Debate concerning the optimal blockage of the renin-angiotensin system].
    Choukroun G
    Nephrol Ther; 2010 Jan; 6 Spec No 1():H1-9. PubMed ID: 20129454
    [No Abstract]   [Full Text] [Related]  

  • 11. Effects of suspending ACE inhibitors and ARBs in advanced chronic kidney disease.
    Díaz-Domínguez ME; Fernández-Lucas M; Gomis-Couto A; Ruiz-Roso G; Teruel JL; Quereda C
    Nefrologia; 2012 May; 32(3):400-1. PubMed ID: 22592428
    [No Abstract]   [Full Text] [Related]  

  • 12. Renoprotective effects of renin-angiotensin-system inhibitors.
    de Zeeuw D; Lewis EJ; Remuzzi G; Brenner BM; Cooper ME
    Lancet; 2006 Mar; 367(9514):899-900; author reply 900-2. PubMed ID: 16546533
    [No Abstract]   [Full Text] [Related]  

  • 13. Inhibition of the renin-angiotensin system: added value in reducing cardiovascular and renal risk?
    Marshall SM
    Diabet Med; 2004 Jan; 21(1):1-3. PubMed ID: 14706047
    [No Abstract]   [Full Text] [Related]  

  • 14. Renin-Angiotensin System Blockage and Avoiding High Doses of Calcineurin Inhibitors Prevent Interstitial Fibrosis and Tubular Atrophy in Kidney Transplant Recipients.
    Sayin B; Canver B; Gurlek Demirci B; Colak T; Ozdemir BH; Haberal M
    Exp Clin Transplant; 2017 Feb; 15(Suppl 1):32-36. PubMed ID: 28260428
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mitigation of radiation injuries via suppression of the renin-angiotensin system: emphasis on radiation nephropathy.
    Cohen EP; Fish BL; Moulder JE
    Curr Drug Targets; 2010 Nov; 11(11):1423-9. PubMed ID: 20583975
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Renin-angiotensin-aldosterone system blockade and urinary albumin excretion in community-based patients with Type 2 diabetes: the Fremantle Diabetes Study.
    Fegan PG; Davis WA; Kamber N; Sivakumar S; Beilby J; Davis TM
    Diabet Med; 2011 Jul; 28(7):849-55. PubMed ID: 21231957
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dual renin-angiotensin system blockade for nephroprotection.
    Ruggenenti P
    Nephrol Ther; 2017 Apr; 13 Suppl 1():S43-S45. PubMed ID: 28577742
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Angiotensin-converting enzyme inhibitor or Angiotensin receptor blocker use and renal outcomes-reply.
    Hsu CC; Liu JS; Tarng DC
    JAMA Intern Med; 2014 Oct; 174(10):1706-7. PubMed ID: 25285739
    [No Abstract]   [Full Text] [Related]  

  • 19. Detecting and controlling diabetic nephropathy: what do we know?
    Appel G
    Cleve Clin J Med; 2013 Apr; 80(4):209-17. PubMed ID: 23547091
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Renin-Angiotensin system blockers and cardiovascular death in kidney recipients.
    Opelz G; Döhler B
    Transplantation; 2014 May; 97(10):e62-3. PubMed ID: 24827898
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.